

## Global Atrial Fibrillation Market – Treatment Types and End-User Facilities

“The report reviews, analyzes and projects the global market for Atrial Fibrillation for the period 2018-2027. The sub-types included in this report for Non-Pharmacological AF treatment includes Catheter Ablation, Electric Cardioversion, High Intensity Focused Ultrasound (HIFU), Maze Surgery and Other Ablation Treatments. Pharmacological Treatment sub-types’ market for AF in this study comprises Blood Thinners, Heart Rate Drugs and Heart Rhythm Drugs. The End-User Facility market for AF explored in this report includes Ambulatory Surgical Centers, Cardiac Centers and Hospitals.”

Published: May 2022

Report Code: HC033

Pages: 246

Charts: 194


Price: \$4050 Single User License, \$6750 Enterprise License

### Report Synopsis

Atrial Fibrillation (AF) is the most common arrhythmia, which can lead to stroke, peripheral embolization, heart failure and other unfavorable outcomes. While the incidence of AF among the general population has been found to be at about 2.3%-3.4%, this registers a significant increase in patients with pulmonary disease, critical illness or systemic inflammatory response syndrome, with devastating clinical impact. A number of recent epidemiological studies have established a greater risk of AF and new-onset AF among patients with COVID-19, though the results have been quite inconsistent. The literature available thus far has indicated that AF or new-onset AF can have a substantial association with the worst outcomes, viz., mortality, in patients with COVID-19.

Apart from the recent development of COVID-19 and its effect on AF, other factors that increase the risk of this condition include growing worldwide prevalence of obesity and heart diseases. The rise in the number of AF cases is fueling the market for treating this disease, though at the same time posing a crushing burden on the economies of several countries because of the high treatment cost involved.

Global Non-Pharmacological Treatment of AF Market by Sub-Type (2019-2027)



Source: Industry Experts, Inc. <https://industry-experts.com>

### Research Findings & Coverage

- Global Atrial Fibrillation market is analyzed in this report with respect to treatment type/sub-type, end-user facilities
- The study exclusively analyzes the market size of each treatment type/sub-type and end-user facility of Atrial Fibrillation by all major geographic regions/countries
- Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrhythmias
- Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
- Thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
- Revolutionary Catheter Ablation Technologies for AF Take Centerstage
- Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
- Major companies profiled – 19
- The industry guide includes the contact details for 70 companies

### Product Outline

The report analyzes the market for the following key treatment types/sub-types of Atrial Fibrillation:

- Non-Pharmacological Treatment
  - Catheter Ablation
  - Electric Cardioversion
  - High Intensity Focused Ultrasound (HIFU)
  - Maze Surgery
  - Other Ablation Treatments
- Pharmacological Treatment
  - Blood Thinners
  - Heart Rate Drugs
  - Heart Rhythm Drugs

End-User Facilities of Atrial Fibrillation analyzed in this study comprise the following:

- Ambulatory Surgical Centers
- Cardiac Centers
- Hospitals

### Analysis Period, Units and Growth Rates

- The report reviews, analyzes and projects the global Atrial Fibrillation market for the period 2018-2027 in terms of market value in US\$ and the compound annual growth rates (CAGRs) projected from 2022 through 2027 with a special focus on y-o-y growth for 2019, 2020 and 2021

### Geographic Coverage

- **North America** (The United States, Canada and Mexico)
- **Europe** (France, Germany, Italy, the United Kingdom and Rest of Europe)
- **Asia-Pacific** (China, India, Japan and Rest of Asia-Pacific)
- **Rest of World**

## SAMPLE COMPANY PROFILE

### MEDTRONIC PLC (IRELAND)

20, Lower Hatch Street, Dublin 2, Ireland  
Phone: 353 1 4381700  
www.medtronic.com

#### Business Overview

Medtronic Plc engages in the manufacture and distribution of an extensive variety of used in treating or managing different conditions, such as chronic pain, obesity, Down syndrome, cardiovascular disorders, diabetes, respiratory disorders and kidney disorders, among others. These offerings are developed through the company’s operating units comprising cardiac rhythm disease management, spinal & biologics, diabetes, cardiovascular and neuromodulation.

#### Product Portfolio

Product Category	Particulars
Advanced Surgical Technology	Ablation Systems, Electrosurgical Hardware, Electrosurgical Instruments, Hemostats, Smoke Evacuation Systems, Ultrasonic Dissection and Vessel Sealing
Cardiac Rhythm	Ablation Products for Arrhythmias, Ablation Products for Atrial Fibrillation, Cardiac Diagnostics & Monitoring, Cardiac Mapping Products, EP Recording System, Cardiac Resynchronisation Therapy (CRT) Devices, Electrosurgical Products, Implantable Cardiac Defibrillator (ICD) Systems, Infection Control, Pacing Systems and Ventricular Assist Devices (VAD)
Cardiovascular	<p>Cardiac Products</p> <p>Ablation Products for Renal Denervation, Ablation Products — Surgical, Blood Management and Diagnostics, Cannulae, Cardiopulmonary Products, Electrosurgical Products, Extracorporeal Life Support (ECLS), Heart Valves (Surgical, Transcatheter Aortic &amp; Transcatheter Pulmonary), Pediatric Perfusion Products and Revascularization Products (Surgical)</p> <p>Vascular Products</p> <p>Aortic Stent Graft Products, Chronic Total Occlusion Devices, Coronary Stents, Coronary Catheters, Coronary Balloons, Coronary Guidewires, Deep Venous Products, Directional Atherectomy Systems, Drug-Coated Balloons, Embolic Protection Devices, Guidewires, Infusion Therapy Products, Peripheral and Biliary Stents, Peripheral Embolization Products, PTA Balloons, Snares, Superficial Vein Products and Support Catheters</p>


.....more

## SAMPLE TABLE/CHART

Glance at 2021 Global Atrial Fibrillation Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific and Rest of World



North American Atrial Fibrillation Non-Pharmacological Treatment Market Analysis (2018-2027) by Sub-Type – Catheter Ablation, Electric Cardioversion, High Intensity Focused Ultrasound (HIFU), Maze Surgery and Other Ablation Treatments in USD Million



## KEY PLAYERS PROFILED

- Abbott Laboratories
- Atricure, Inc.
- Biosense Webster, Inc.
- Biotronik SE & Co. Kg
- Boehringer Ingelheim International GmbH
- Boston Scientific Corporation
- Bristol-Myers Squibb Co.
- Cardiofocus, Inc.
- Cathrx Ltd
- Medtronic Plc
- Osypka AG
- Pfizer Inc.
- Shanghai Microport Medical (Group) Co Ltd
- Siemens Medical Solutions USA, Inc.

.....more

## TABLE OF CONTENTS

### PART A: GLOBAL MARKET PERSPECTIVE ..... 1

#### 1. INTRODUCTION .....1

1.1 Product Outline.....	5
1.1.1 An Overview of Atrial Fibrillation.....	5
1.1.1.1 Classification of AF.....	6
1.1.1.1.1 Paroxysmal (Self-Terminating or Intermittent) Atrial Fibrillation.....	6
1.1.1.1.2 Persistent Atrial Fibrillation.....	6
1.1.1.1.3 Permanent Atrial Fibrillation.....	6
1.1.1.1.4 Lone Atrial Fibrillation.....	6
1.1.1.2 Clinical Features.....	6
1.1.1.3 Risk factors for Atrial Fibrillation.....	7
1.1.1.3.1 Clinical Risk Factors.....	7
1.1.1.3.2 Reversible Risk Factors.....	7
1.1.1.3.3 Nonmodifiable Factors.....	8
1.1.1.3.4 Emerging Risk Factors.....	8
1.1.2 Treatment of Atrial Fibrillation (AF).....	8
1.1.2.1 Non-Pharmacological Treatments.....	8
1.1.2.1.1 Catheter Ablation.....	8
1.1.2.1.2 Electric Cardioversion.....	9
1.1.2.1.3 High Intensity Focused Ultrasound (HIFU) ..	9
1.1.2.1.4 Maze Surgery.....	10
1.1.2.1.5 Other Ablation Treatments.....	10
1.1.2.1.5.1 Cryoablation.....	10
1.1.2.1.5.2 Microwave Ablation.....	10
1.1.2.1.5.3 Radiofrequency Ablation.....	11
1.1.2.2 Pharmacological Treatments.....	11
1.1.2.2.1 Blood Thinners.....	11
1.1.2.2.1.1 Antiplatelet Drugs.....	12
1.1.2.2.1.2 Anticoagulants Drugs.....	12
1.1.2.2.2 Heart Rate Drugs.....	12
1.1.2.2.2.1 Beta-Blockers.....	12
1.1.2.2.2.2 Calcium Channel Blockers.....	12
1.1.2.2.2.3 Digitalis Glycosides.....	13
1.1.2.2.3 Heart Rhythm Drugs.....	13
1.1.2.2.3.1 Sodium Channel Blockers.....	13
1.1.2.2.3.2 Potassium Channel Blockers.....	13

#### 2. AF TREATMENT BY END-USER FACILITIES – MARKET SNAPSHOT .....14

2.1 Ambulatory Surgical Centers.....	14
2.2 Cardiac Centers.....	16
2.3 Hospitals.....	17

#### 3. KEY MARKET TRENDS.....18

3.1 Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrhythmias.....	18
3.2 Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF).....	19
3.3 Thumb ECGs Playing a Greater Role Atrial Fibrillation Detection.....	21
3.4 Atrial Fibrillation Treated Successfully through Pulsed Field Ablation.....	22
3.5 Revolutionary Catheter Ablation Technologies for AF Take Centerstage.....	22

#### 4. KEY GLOBAL PLAYERS.....23

Abbott Laboratories (United States).....	23
Atricure, Inc. (United States).....	24
Biosense Webster, Inc. (United States).....	25
Biotronik Se & Co. Kg (Germany).....	26
Boehringer Ingelheim International GmbH (Germany).....	27
Boston Scientific Corporation (United States).....	28
Bristol-Myers Squibb Co. (United States).....	29
Cardiofocus, Inc. (United States).....	30
Cathrx Ltd (Australia).....	30
Medtronic Plc (Ireland).....	31
Ospyka Ag (Germany).....	33
Pfizer Inc. (United States).....	34
Shanghai Micropor Medical (Group) Co Ltd (China).....	35
Siemens Medical Solutions Usa, Inc. (United States).....	35

### 5. KEY BUSINESS & PRODUCT TRENDS.....36

Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial.....	36
Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device.....	36
Boston Scientific Closes Acquisition of Baylis Medical Company Inc.....	36
Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition.....	36
Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms.....	36
Acutus Medical's Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium.....	36
Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System.....	36
Medtronic to Acquire Affera.....	36
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial.....	36
Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation.....	36
Continuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrillation Episodes and Ischemic Stroke.....	36
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC.....	36
Biosense Webster Announces Completion of Atrial Fibrillation Cases Using Novel HELIOSTAR™ Balloon Ablation Catheter.....	36
New Data & Innovations: Heart Rhythm 2021.....	36
BIOTRONIK Expands Range of Peripheral Introducer Sheaths.....	36
CardioFocus-Announces-Agreement-to-Acquire-Intellectual-Property-Press-Release.pdf.....	36
Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman® Device for People With Atrial Fibrillation at Risk of Stroke.....	36
Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke.....	36
AcQMap 8, Acutus Medical's Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark.....	36
Real-World Data Demonstrate Significant Reduction in Complications and Reinterventions with Medtronic Micra Leadless Pacemaker.....	36
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients.....	37
Abbott Receives European And Canadian Approval For Amplatzer™ Steerable Delivery Sheath To Optimize Left Atrial Appendage Closure Procedures For People At Risk Of Stroke.....	37
Medtronic Receives FDA Expanded Approval for Arctic Front™ Family of Cardiac Cryoablation Catheters for Initial Use for Recurrent Symptomatic Paroxysmal Atrial Fibrillation.....	37
Abbott Introduces Jot Dx™ Insertable Cardiac Monitor, Designed To Reduce Data Burden And Improve Accurate Diagnosis Of Difficult-To-Detect Abnormal Heart Rhythms.....	37
AliveCor and Acutus Medical Partner to Evaluate Management and Treatment of Cardiac Arrhythmias.....	37
New Data & Innovations: Heart Rhythm 2021.....	37
BIOTRONIK's Cardiac Monitor Receives Prestigious Award.....	37
Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device.....	37
CardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021.....	37
CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan.....	37
Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring.....	37
CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China.....	37
GE Healthcare and the American College of Cardiology Join Forces to Advance AI in Cardiac Care.....	37

Medtronic Launches App-Based Study to Better Understand Relationship Between Atrial Fibrillation Disease Burden and Impact on Patient Outcomes.....	37
Siemens Healthineers Receives CE Mark for the ACUSON AcuNav Volume ICE Catheter.....	37
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial.....	37
Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System.....	37
Japan Lifeline Finalizes Supply Agreement for Pulsed Electric Field Ablation Catheter for U.S. Market.....	37
Acutus Medical Announces FDA Clearance of AcqCross™, a Full Suite of Universal Transseptal Crossing Devices.....	37
Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate® FORCE Sensing Ablation System.....	37
AtriCure's EPI-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients.....	37
Acutus Medical Receives Vizient Innovative Technology Contract.....	37
Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation.....	37
CardioFocus Announces Expanded Partnership With Japan Lifeline.....	37
CardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And Portugal.....	38
Medtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation.....	38
Acutus Medical Announces CE Mark and European Launch of AcqCross™ Transseptal System, a Fully Integrated Family of Transseptal Crossing Products.....	38
CardioFocus Announces 10,000 Patients Treated Worldwide.....	38
First Clinical Implantation of MicroPort® Left.....	38
Abbott Introduces Next-Generation 3d Cardiac Mapping Platform In Europe And Australia.....	38
The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy.....	38
Acutus Medical Launches AcQBlate® Force Sensing Ablation System in Europe.....	38
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation.....	38
Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping Catheter.....	38
Acutus Medical Announces Pulsed Field Ablation Program and Initial Pre-Clinical Results.....	38
Medtronic Gains FDA Clearance, CE Mark for LINQ II™ Insertable Cardiac Monitor (ICM).....	38
Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring.....	38
Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support.....	38
Medtronic Micra™ AV Receives CE Mark.....	38
New Alliance Maps the Way in Electrophysiology.....	38
CardioFocus Announces US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation.....	38
GE Healthcare and Preventice Solutions Collaborate to Connect the Heart, the Hospital and the Home Seamlessly.....	38
Bristol Myers Squibb - The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis.....	38

### 6. GLOBAL MARKET OVERVIEW .....39

6.1 Global Atrial Fibrillation Market Overview by Treatment Type.....	40
6.1.1 Global Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type.....	42
6.1.2 Global Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type.....	44

6.1.3 Atrial Fibrillation Treatment Type Market  
 Overview by Global Region ..... 46  
 6.1.3.1 Non-Pharmacological ..... 46  
 6.1.3.1.1 Atrial Fibrillation's Non-Pharmacological  
 Treatment Sub-Type Market Overview by Global  
 Region ..... 48  
 6.1.3.1.1.1 Catheter Ablation ..... 48  
 6.1.3.1.1.2 Electric Cardioversion ..... 50  
 6.1.3.1.1.3 High Intensity Focused Ultrasound (HIFU) ... 52  
 6.1.3.1.1.4 Maze Surgery ..... 54  
 6.1.3.1.1.5 Other Ablation Treatments ..... 56  
 6.1.3.2 Pharmacological ..... 58  
 6.1.3.2.1 Atrial Fibrillation's Pharmacological  
 Treatment Sub-Type Market Overview by Global  
 Region ..... 60  
 6.1.3.2.1.1 Blood Thinners ..... 60  
 6.1.3.2.1.2 Heart Rate Drugs ..... 62  
 6.1.3.2.1.3 Heart Rhythm Drugs ..... 64  
 6.2 Global Atrial Fibrillation Market Overview by End-  
 User Facility ..... 66  
 6.2.1 Atrial Fibrillation End-User Facility Market  
 Overview by Global Region ..... 68  
 6.2.1.1 Ambulatory Surgical Centers ..... 68  
 6.2.1.2 Cardiac Centers ..... 70  
 6.2.1.3 Hospitals ..... 72

**PART B: REGIONAL MARKET PERSPECTIVE ... 74**  
**REGIONAL MARKET OVERVIEW ..... 76**  
**7. NORTH AMERICA ..... 76**  
 7.1 North American Atrial Fibrillation Market  
 Overview by Geographic Region ..... 77  
 7.2 North American Atrial Fibrillation Market  
 Overview by Treatment Type ..... 79  
 7.2.1 North American Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 81  
 7.2.2 North American Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 83  
 7.3 North American Atrial Fibrillation Market  
 Overview by End-User Facility ..... 85  
 7.4 Major Market Players ..... 87  
 Abbott Laboratories (United States) ..... 87  
 Acutus Medical, Inc. (United States) ..... 88  
 Atricure, Inc. (United States) ..... 89  
 Biosense Webster, Inc. (United States) ..... 90  
 Boston Scientific Corporation (United States) ..... 91  
 Bristol-Myers Squibb Co. (United States) ..... 92  
 Cardiofocus, Inc. (United States) ..... 93  
 Ge Healthcare (United States) ..... 93  
 Pfizer Inc. (United States) ..... 94  
 Siemens Medical Solutions Usa, Inc. (United States) ..... 94  
 7.5 Country-wise Analysis of North American Atrial  
 Fibrillation Market ..... 95  
**7.5.1 The United States ..... 95**  
 7.5.1.1 United States' Atrial Fibrillation Market  
 Overview by Treatment Type ..... 96  
 7.5.1.1.1 United States' Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 98  
 7.5.1.1.2 United States' Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 100  
 7.5.1.2 United States' Atrial Fibrillation Market  
 Overview by End-User Facility ..... 102  
**7.5.2 Canada ..... 104**  
 7.5.2.1 Canadian Atrial Fibrillation Market Overview  
 by Treatment Type ..... 105  
 7.5.2.1.1 Canadian Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 107  
 7.5.2.1.2 Canadian Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 109  
 7.5.2.2 Canadian Atrial Fibrillation Market Overview  
 by End-User Facility ..... 111

**7.5.3 Mexico ..... 113**  
 7.5.3.1 Mexican Atrial Fibrillation Market Overview by  
 Treatment Type ..... 114  
 7.5.3.1.1 Mexican Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 116  
 7.5.3.1.2 Mexican Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 118  
 7.5.3.2 Mexican Atrial Fibrillation Market Overview by  
 End-User Facility ..... 120

**8. EUROPE ..... 122**  
 8.1 European Atrial Fibrillation Market Overview by  
 Geographic Region ..... 123  
 8.2 European Atrial Fibrillation Market Overview by  
 Treatment Type ..... 125  
 8.2.1 European Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 127  
 8.2.2 European Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 129  
 8.3 European Atrial Fibrillation Market Overview by  
 End-User Facility ..... 131  
 8.4 Major Market Players ..... 133  
 Acesion Pharma (Denmark) ..... 133  
 Afreeze GmbH (Austria) ..... 133  
 Biotronik Se & Co. Kg (Germany) ..... 134  
 Boehringer Ingelheim International GmbH (Germany) . 135  
 Medtronic Plc (Ireland) ..... 136  
 Osypka Ag (Germany) ..... 138

8.5 Country-wise Analysis of European Atrial  
 Fibrillation Market ..... 139  
**8.5.1 France ..... 139**  
 8.5.1.1 French Atrial Fibrillation Market Overview by  
 Treatment Type ..... 140  
 8.5.1.1.1 French Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 142  
 8.5.1.1.2 French Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 144  
 8.5.1.2 French Atrial Fibrillation Market Overview by  
 End-User Facility ..... 146  
**8.5.2 Germany ..... 148**  
 8.5.2.1 German Atrial Fibrillation Market Overview by  
 Treatment Type ..... 149  
 8.5.2.1.1 German Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 151  
 8.5.2.1.2 German Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 153  
 8.5.2.2 German Atrial Fibrillation Market Overview by  
 End-User Facility ..... 155  
**8.5.3 Italy ..... 157**  
 8.5.3.1 Italian Atrial Fibrillation Market Overview by  
 Treatment Type ..... 158  
 8.5.3.1.1 Italian Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 160  
 8.5.3.1.2 Italian Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 162  
 8.5.3.2 Italian Atrial Fibrillation Market Overview by  
 End-User Facility ..... 164  
**8.5.4 The United Kingdom ..... 166**  
 8.5.4.1 United Kingdom Atrial Fibrillation Market  
 Overview by Treatment Type ..... 167  
 8.5.4.1.1 United Kingdom Atrial Fibrillation Non-  
 Pharmacological Treatment Market Overview by Sub-  
 Type ..... 169  
 8.5.4.1.2 United Kingdom Atrial Fibrillation  
 Pharmacological Treatment Market Overview by Sub-  
 Type ..... 171  
 8.5.4.2 United Kingdom Atrial Fibrillation Market  
 Overview by End-User Facility ..... 173

**8.5.5 Rest of Europe ..... 175**  
 8.5.5.1 Rest of Europe Atrial Fibrillation Market  
 Overview by Treatment Type ..... 176  
 8.5.5.1.1 Rest of Europe Atrial Fibrillation Non-  
 Pharmacological Treatment Market Overview by Sub-  
 Type ..... 178  
 8.5.5.1.2 Rest of Europe Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 180  
 8.5.5.2 Rest of Europe Atrial Fibrillation Market  
 Overview by End-User Facility ..... 182

**9. ASIA-PACIFIC ..... 184**  
 9.1 Asia-Pacific Atrial Fibrillation Market Overview by  
 Geographic Region ..... 185  
 9.2 Asia-Pacific Atrial Fibrillation Market Overview by  
 Treatment Type ..... 187  
 9.2.1 Asia-Pacific Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 189  
 9.2.2 Asia-Pacific Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 191  
 9.3 Asia-Pacific Atrial Fibrillation Market Overview by  
 End-User Facility ..... 193  
 9.4 Major Market Players ..... 195  
 Cathrx Ltd (Australia) ..... 195  
 Japan Lifeline Co. (Japan) ..... 195  
 Shanghai Microport Medical (Group) Co Ltd (China) .... 196  
 9.5 Country-wise Analysis of Asia-Pacific Atrial  
 Fibrillation Market ..... 197  
**9.5.1 China ..... 197**  
 9.5.1.1 Chinese Atrial Fibrillation Market Overview by  
 Treatment Type ..... 198  
 9.5.1.1.1 Chinese Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 200  
 9.5.1.1.2 Chinese Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 202  
 9.5.1.2 Chinese Atrial Fibrillation Market Overview by  
 End-User Facility ..... 204  
**9.5.2 India ..... 206**  
 9.5.2.1 Indian Atrial Fibrillation Market Overview by  
 Treatment Type ..... 207  
 9.5.2.1.1 Indian Atrial Fibrillation Non-  
 Pharmacological Treatment Market Overview by Sub-  
 Type ..... 209  
 9.5.2.1.2 Indian Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 211  
 9.5.2.2 Indian Atrial Fibrillation Market Overview by  
 End-User Facility ..... 213  
**9.5.3 Japan ..... 215**  
 9.5.3.1 Japanese Atrial Fibrillation Market Overview  
 by Treatment Type ..... 216  
 9.5.3.1.1 Japanese Atrial Fibrillation Non-Pharmacological  
 Treatment Market Overview by Sub-Type ..... 218  
 9.5.3.1.2 Japanese Atrial Fibrillation Pharmacological  
 Treatment Market Overview by Sub-Type ..... 220  
 9.5.3.2 Japanese Atrial Fibrillation Market Overview  
 by End-User Facility ..... 222  
**9.5.4 Rest of Asia-Pacific ..... 224**  
 9.5.4.1 Rest of Asia-Pacific Atrial Fibrillation Market  
 Overview by Treatment Type ..... 225  
 9.5.4.1.1 Rest of Asia-Pacific Atrial Fibrillation Non-  
 Pharmacological Treatment Market Overview by Sub-  
 Type ..... 227  
 9.5.4.1.2 Rest of Asia-Pacific Atrial Fibrillation  
 Pharmacological Treatment Market Overview by Sub-  
 Type ..... 229  
 9.5.4.2 Rest of Asia-Pacific Atrial Fibrillation Market  
 Overview by End-User Facility ..... 231

<b>10. REST OF WORLD.....</b>	<b>233</b>	<b>PART C: GUIDE TO THE INDUSTRY.....</b>	<b>242</b>
10.1 Rest of World Atrial Fibrillation Market Overview by Treatment Type .....	234	NORTH AMERICA .....	242
10.1.1 Rest of World Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type .....	236	EUROPE .....	243
10.1.2 Rest of World Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type .....	238	ASIA-PACIFIC.....	244
10.2 Rest of World Atrial Fibrillation Market Overview by End-User Facility .....	240	REST OF WORLD .....	244
		<b>PART D: ANNEXURE.....</b>	<b>245</b>
		1. RESEARCH METHODOLOGY .....	245
		2. FEEDBACK .....	247

## About Industry Experts

Industry Experts’ market research, backed by years of experience and an analytical team dedicated to providing the most optimal business solutions, has been specifically designed to provide a variety of benefits, both current and future. Our leading-edge publications make the life easy for corporate strategists, investors, analysts and researchers, startups, consultants, financial and banking executives, academicians and many more. The company also provides customized research reports to cater the needs of the industry.

Business intelligence provides the critical link between comprehending prevailing market conditions and devising strategies to maximize parameters, such as revenues, profits and return on investment in order to gain market share. The significance of market research can be largely understood through the range of factors that impact businesses. These can comprise market size (current and projected), geographic market reach and demand and supply scenario, to name a few. Our ongoing quest to collect up to date and accurate information by conducting online surveys, personal interviews, taking the opinions of senior level executives will enable us to serve our clients better in every possible aspect.

**More about Industry Experts**



**Industry Experts, Inc.**  
 451 W Bonita Ave, Suite #10  
 San Dimas, CA 91710  
 Greater Los Angeles, United States  
 Phone: +1-320-iXPERTS (497-3787)  
 Email: [info@industry-experts.com](mailto:info@industry-experts.com)

**India Office**  
 1-7-19/C, Street No. 8, Habsiguda  
 Hyderabad – 500007  
 India  
 Phone: +91-40-2715-7746  
 Website: <https://industry-experts.com>